We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » The FDA's Corporatewide View of cGMP Violations: A Systemic Approach
The FDA's Corporatewide View of cGMP Violations: A Systemic Approach
April 2, 2007
Manufacturers should approach their responses to Form 483s and FDA warning letters with a global perspective, experts said at
an FDAnews audioconference March 27.